Poly Medicure Q2 FY26 Financial Results & Strategic Update

Poly Medicure Ltd. (Polymed) has announced its financial results for the second quarter ending September 30, 2025, Q2 FY26 Financial Highlights Net Profit: The company reported a 5% year-on-year (YoY) increase in net profit, reaching ₹91.83 crore compared to ₹87.45 crore in the corresponding period last year. Revenue from Operations: Consolidated revenue grew 5.7% YoY to ₹443.9 crore. This growth was significantly bolstered by a strong performance in the domestic market. Domestic Revenue: Domestic sales delivered robust growth, jumping 16.9% YoY, underscoring strong brand traction and market penetration. EBITDA & Margins: Earnings before interest, tax, depreciation, and amortisation (EBITDA) was stable at ₹114.68 crore. Operating margins stood at 25.84% (vs. 27.43% in Q2 FY25). Strategic Expansion & Innovation Polymed has achieved key milestones in its strategic expansion into high-growth therapeutic segments: Key Acquisitions Completed: The company successfully completed the acquisitions of the PendraCare Group in the Netherlands (strengthening its cardiology portfolio) and the Citieffe Group in Italy (marking a strategic entry into the orthopaedics segment). Innovation Pipeline: The company launched 8 new products during the quarter, supported by a dedicated R&D team of over 80 professionals. Clinical Traction: The cardiology portfolio continues to gain momentum, with over 4,300 stents implanted year-to-date, yielding positive clinical feedback. H1 FY26 & Balance Sheet Strength H1 Performance: For the first half of FY26, consolidated PAT grew 14.5% YoY, with EBITDA margins tracking near the higher end of the 25-27% guidance range. Balance Sheet: The company maintains a strong liquidity position, with cash reserves of ₹1,109.1 crore as of September 30, 2025. Future Expansion: Polymed received an allotment for a 7.16-acre plot at the Medical Devices Park (YEIDA), securing capacity for future growth.